欧普康视：盐酸毛果芸香碱滴眼液获得《药物临床试验批准通知书》

Company Overview - Opcon Vision (SZ 300595) announced on December 5 that it received the "Drug Clinical Trial Approval Notification" from the National Medical Products Administration for its "Pilocarpine Hydrochloride Eye Drops" to conduct clinical trials [1] - As of the report date, Opcon Vision has a market capitalization of 14 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Opcon Vision is as follows: - Rigid contact lens industry accounts for 56.18% - Medical industry accounts for 20.04% - Other optometry and professional services account for 19.47% - Non-optometry and others account for 4.31% [1]